How much funding has Clementia raised?

Clementia has raised $92.5M in total funding, most recently a Venture Round.

Who are Clementia's investors?

Clementia's investors include OrbiMed, New Enterprise Associates, UCB, RA Capital Management, Rock Springs Capital, EcoR1 Capital.

Where is Clementia headquartered?

Clementia is headquartered in Montreal, Canada.

What industry is Clementia in?

Clementia operates in Biotech, Rare Diseases.

Clementia

IPO

Public · Montreal, Canada · Founded 2013 · $92.5M raised

Biotech

Rare Diseases

Headquarters: Montreal
Employees: 11–50
Founded: 2013
Business Model: B2B
Website: clementiapharma.com

Total Funding: $92.5M
Last Round: $60.0M Venture RoundJun 2015
Rounds: 3
Type: Public

About

Clementia Pharmaceuticals was a Montreal-based rare disease biopharmaceutical company founded in 2011. Its lead compound palovarotene, a retinoic acid receptor gamma agonist, was in clinical development for fibrodysplasia ossificans progressiva and multiple osteochondromas. Clementia was acquired by Ipsen in 2019 for approximately $1.3 billion.

Summary

Clementia is a Biotech company based in Montreal, Canada, founded in 2013. It has raised $92.5M in total across 3 rounds, most recently a $60.0M Venture Round round in Jun 2015. Investors include OrbiMed, New Enterprise Associates and UCB.